0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Dealing with uncertainty in the treatment of Helicobacter pylori

      1
      Therapeutic Advances in Chronic Disease
      SAGE Publications

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d13344740e109"> <i>Helicobacter pylori</i> treatment may be viewed as an uncertain situation, where current knowledge is insufficient to provide evidence-based recommendations for all possible scenarios. Evidence suggests that, under uncertainty conditions, a few simple rules of thumb tend to work better than complex algorithms. Overall, five evidence-based rules of thumb are suggested: (1) Use four drugs; (2) Use maximal acid inhibition; (3) Treat for 2 weeks; (4) Do not repeat antibiotics after treatment failure; and (5) If your treatment works locally, keep using it. These simple rules of thumb may help the reader to select the best alternative for a given patient, choosing between the heterogeneous recommendations provided by the many different consensus conferences on <i>H. pylori</i> treatment recently published. </p>

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.

          Helicobacter pylori infection is increasingly difficult to treat. The purpose of these consensus statements is to provide a review of the literature and specific, updated recommendations for eradication therapy in adults.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.

            Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related diseases. Vonoprazan is a member of a new class of acid suppressants; potassium-competitive acid blockers. Vonoprazan may thus be an alternative to PPIs.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review.

              The urea breath test is a non-invasive, simple and safe test which provides excellent accuracy both for the initial diagnosis of Helicobacter pylori infection and for the confirmation of its eradication after treatment. Some studies have found no differences between urea breath test performed under non-fasting conditions. The simplicity, good tolerance and economy of the citric acid test meal probably make its systematic use advisable. The urea breath test protocol may be performed with relatively low doses (<100 mg) of urea: 75 mg or even 50 mg seem to be sufficient. With the most widely used protocol (with citric acid and 75 mg of urea), excellent accuracy is obtained when breath samples are collected as early as 10-15 min after urea ingestion. A unique and generally proposed cut-off level is not possible because it has to be adapted to different factors, such as the test meal, the dose and type of urea, or the pre-/post-treatment setting. Fortunately, because positive and negative urea breath test results tend to cluster outside of the range between 2 and 5 per thousand, a change in cut-off value within this range would be expected to have little effect on clinical accuracy of the test.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                Journal
                Therapeutic Advances in Chronic Disease
                Therapeutic Advances in Chronic Disease
                SAGE Publications
                2040-6223
                2040-6231
                February 12 2018
                April 2018
                February 12 2018
                April 2018
                : 9
                : 4
                : 93-102
                Affiliations
                [1 ]Servei de Malalties Digestives, Hospital de Sabadell., Departament de Medicina, Universitat Autònoma de Barcelona, CIBEREHD – Instituto de Salud Carlos III, Parc Taulí, 1, 08208 Sabadell (Barcelona), Spain
                Article
                10.1177/2040622318758240
                5881993
                29623181
                6f8e5a7d-f53e-42ea-bf06-c8752e5c5668
                © 2018

                http://journals.sagepub.com/page/policies/text-and-data-mining-license

                History

                Comments

                Comment on this article